- Home
- WT vs VCEL Comparison
WT vs VCEL Comparison
Compare WT & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WT | VCEL |
|---|---|---|
| Founded | 1985 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2011 | 1996 |
Fundamental Metrics
Financial Performance| Metric | WT | VCEL |
|---|---|---|
| Price | $16.54 | $33.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $17.08 | ★ $58.50 |
| AVG Volume (30 Days) | ★ 2.4M | 424.1K |
| Earning Date | 05-01-2026 | 05-18-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 127.27 | 60.00 |
| EPS | ★ 0.75 | 0.32 |
| Revenue | ★ $493,753,000.00 | $276,259,000.00 |
| Revenue This Year | $33.08 | $20.11 |
| Revenue Next Year | $7.39 | $19.40 |
| P/E Ratio | ★ $22.87 | $106.22 |
| Revenue Growth | 15.43 | ★ 16.45 |
| 52 Week Low | $7.47 | $29.24 |
| 52 Week High | $17.68 | $49.38 |
Technical Indicators
Market Signals| Indicator | WT | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 37.46 |
| Support Level | $15.38 | $29.59 |
| Resistance Level | $17.09 | $38.48 |
| Average True Range (ATR) | 0.66 | 1.57 |
| MACD | -0.09 | -0.34 |
| Stochastic Oscillator | 45.48 | 10.53 |
Price Performance
Historical ComparisonAbout WT WisdomTree Inc.
WisdomTree Inc is a financial innovator, offering a well-diversified suite of exchange-traded products (ETPs), models and solutions. It offers a broad range of ETFs and exchange-traded products (ETPs). The firm also engages in developing next-generation digital products and structures, including digital funds and tokenized assets, as well as its blockchain-native digital wallet, WisdomTree Prime. The Company conducts business under a single operating segment as an ETP sponsor and asset manager.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.